 Zachary Watson
Concepts (119)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ovarian Neoplasms | 9 | 2024 | 586 | 1.700 |
Why?
| | Herpesvirus 1, Human | 5 | 2018 | 84 | 1.530 |
Why?
| | Poly(ADP-ribose) Polymerase Inhibitors | 7 | 2024 | 132 | 1.320 |
Why?
| | Virus Latency | 3 | 2018 | 90 | 0.950 |
Why?
| | Gene Expression Regulation, Viral | 3 | 2018 | 94 | 0.940 |
Why?
| | Phthalazines | 3 | 2023 | 64 | 0.920 |
Why?
| | Histone-Lysine N-Methyltransferase | 3 | 2024 | 141 | 0.910 |
Why?
| | Cystadenocarcinoma, Serous | 3 | 2023 | 84 | 0.900 |
Why?
| | Piperazines | 3 | 2023 | 381 | 0.790 |
Why?
| | Genetic Vectors | 4 | 2019 | 337 | 0.760 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2024 | 883 | 0.740 |
Why?
| | Dependovirus | 3 | 2019 | 79 | 0.740 |
Why?
| | Histocompatibility Antigens | 2 | 2024 | 102 | 0.640 |
Why?
| | Transduction, Genetic | 2 | 2019 | 133 | 0.610 |
Why?
| | Protein-Arginine N-Methyltransferases | 1 | 2019 | 25 | 0.570 |
Why?
| | Virus Activation | 2 | 2018 | 95 | 0.560 |
Why?
| | RNA, Long Noncoding | 1 | 2018 | 178 | 0.470 |
Why?
| | Sensory Receptor Cells | 1 | 2016 | 101 | 0.450 |
Why?
| | Polycomb-Group Proteins | 2 | 2023 | 36 | 0.440 |
Why?
| | RNA, Viral | 1 | 2018 | 688 | 0.420 |
Why?
| | Cell Line, Tumor | 8 | 2024 | 3550 | 0.350 |
Why?
| | Host-Pathogen Interactions | 1 | 2013 | 371 | 0.310 |
Why?
| | Rabbits | 4 | 2019 | 648 | 0.300 |
Why?
| | Trigeminal Ganglion | 2 | 2019 | 26 | 0.270 |
Why?
| | Neoplasms | 2 | 2023 | 2884 | 0.260 |
Why?
| | Ganglia, Spinal | 2 | 2019 | 89 | 0.260 |
Why?
| | Herpes Simplex | 2 | 2018 | 98 | 0.240 |
Why?
| | Histones | 2 | 2023 | 670 | 0.240 |
Why?
| | DNA Degradation, Necrotic | 1 | 2025 | 1 | 0.230 |
Why?
| | Preservation, Biological | 1 | 2025 | 7 | 0.230 |
Why?
| | Cryopreservation | 1 | 2025 | 110 | 0.210 |
Why?
| | Mice | 10 | 2024 | 18365 | 0.210 |
Why?
| | Animals | 14 | 2025 | 38109 | 0.200 |
Why?
| | Specimen Handling | 1 | 2025 | 186 | 0.200 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2024 | 930 | 0.190 |
Why?
| | Polycomb Repressive Complex 1 | 1 | 2023 | 66 | 0.190 |
Why?
| | Epoxy Compounds | 1 | 2020 | 32 | 0.160 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 67 | 0.160 |
Why?
| | Tumor Microenvironment | 2 | 2023 | 735 | 0.150 |
Why?
| | Carnitine O-Palmitoyltransferase | 1 | 2020 | 49 | 0.150 |
Why?
| | Rad51 Recombinase | 1 | 2019 | 15 | 0.150 |
Why?
| | BRCA2 Protein | 1 | 2019 | 67 | 0.150 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2020 | 421 | 0.150 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2019 | 86 | 0.140 |
Why?
| | Neoplasm Grading | 1 | 2019 | 309 | 0.140 |
Why?
| | CCCTC-Binding Factor | 1 | 2018 | 12 | 0.140 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 917 | 0.140 |
Why?
| | DNA | 1 | 2025 | 1464 | 0.140 |
Why?
| | Oncogenes | 1 | 2019 | 119 | 0.140 |
Why?
| | Gene Knockout Techniques | 1 | 2018 | 116 | 0.130 |
Why?
| | RNA, Catalytic | 1 | 2018 | 189 | 0.130 |
Why?
| | Gene Transfer Techniques | 1 | 2019 | 185 | 0.130 |
Why?
| | Neoadjuvant Therapy | 1 | 2020 | 463 | 0.130 |
Why?
| | Sequence Analysis, RNA | 1 | 2019 | 442 | 0.130 |
Why?
| | Up-Regulation | 1 | 2020 | 852 | 0.130 |
Why?
| | Carcinogenesis | 1 | 2019 | 229 | 0.130 |
Why?
| | Fatty Acids | 1 | 2020 | 452 | 0.120 |
Why?
| | Parvoviridae Infections | 1 | 2016 | 12 | 0.120 |
Why?
| | Mass Spectrometry | 1 | 2019 | 750 | 0.120 |
Why?
| | Eye | 1 | 2016 | 109 | 0.110 |
Why?
| | Foot | 1 | 2016 | 100 | 0.110 |
Why?
| | Coinfection | 1 | 2016 | 141 | 0.110 |
Why?
| | Female | 11 | 2024 | 78376 | 0.100 |
Why?
| | Mice, Transgenic | 1 | 2019 | 2185 | 0.100 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1786 | 0.090 |
Why?
| | Anoikis | 2 | 2023 | 30 | 0.090 |
Why?
| | Disease Progression | 1 | 2019 | 2852 | 0.090 |
Why?
| | Transcription, Genetic | 1 | 2018 | 1496 | 0.090 |
Why?
| | Humans | 12 | 2024 | 144957 | 0.080 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2024 | 1462 | 0.080 |
Why?
| | Cells, Cultured | 1 | 2018 | 4155 | 0.080 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1958 | 0.080 |
Why?
| | Neurons | 1 | 2018 | 1642 | 0.070 |
Why?
| | Inflammation | 1 | 2020 | 2880 | 0.070 |
Why?
| | Genetic Therapy | 1 | 2009 | 313 | 0.060 |
Why?
| | Cornea | 2 | 2019 | 155 | 0.060 |
Why?
| | Central Nervous System | 1 | 2009 | 281 | 0.060 |
Why?
| | Breast Neoplasms | 1 | 2019 | 2456 | 0.060 |
Why?
| | Antineoplastic Agents | 1 | 2017 | 2197 | 0.060 |
Why?
| | Freezing | 1 | 2025 | 86 | 0.050 |
Why?
| | Birds | 1 | 2025 | 92 | 0.050 |
Why?
| | Lysine | 1 | 2023 | 302 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2024 | 4569 | 0.040 |
Why?
| | ErbB Receptors | 1 | 2023 | 629 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2020 | 336 | 0.040 |
Why?
| | Indazoles | 1 | 2019 | 80 | 0.040 |
Why?
| | Heterografts | 1 | 2019 | 144 | 0.040 |
Why?
| | Ganglia | 1 | 2018 | 18 | 0.030 |
Why?
| | Injections | 1 | 2019 | 197 | 0.030 |
Why?
| | 3T3 Cells | 1 | 2018 | 156 | 0.030 |
Why?
| | Virus Shedding | 1 | 2018 | 48 | 0.030 |
Why?
| | Transgenes | 1 | 2019 | 190 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2019 | 370 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2020 | 635 | 0.030 |
Why?
| | Piperidines | 1 | 2019 | 217 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1268 | 0.030 |
Why?
| | Cell Culture Techniques | 1 | 2020 | 375 | 0.030 |
Why?
| | Peptides | 1 | 2023 | 998 | 0.030 |
Why?
| | Wnt Signaling Pathway | 1 | 2019 | 210 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2024 | 2499 | 0.030 |
Why?
| | Genome, Viral | 1 | 2018 | 218 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2020 | 1087 | 0.030 |
Why?
| | Survival Rate | 1 | 2020 | 2092 | 0.030 |
Why?
| | Transcription Factors | 1 | 2023 | 1742 | 0.030 |
Why?
| | Indoles | 1 | 2019 | 501 | 0.030 |
Why?
| | Binding Sites | 1 | 2018 | 1331 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2019 | 1718 | 0.030 |
Why?
| | Gene Expression | 1 | 2019 | 1490 | 0.030 |
Why?
| | Prognosis | 1 | 2020 | 4293 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2020 | 5417 | 0.020 |
Why?
| | Genes, Immediate-Early | 1 | 2009 | 26 | 0.020 |
Why?
| | Lac Operon | 1 | 2009 | 44 | 0.020 |
Why?
| | Microinjections | 1 | 2009 | 92 | 0.020 |
Why?
| | CD11c Antigen | 1 | 2009 | 40 | 0.020 |
Why?
| | CD11b Antigen | 1 | 2009 | 60 | 0.020 |
Why?
| | Mutation | 1 | 2019 | 4099 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2009 | 758 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 983 | 0.020 |
Why?
| | Virus Replication | 1 | 2009 | 529 | 0.020 |
Why?
|
|
Watson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|